Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts.

Villain L, Commenges D, Pasin C, Prague M, Thiébaut R.

Stat Med. 2019 Jan 30;38(2):221-235. doi: 10.1002/sim.7957. Epub 2018 Sep 26.


Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.

Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM.

Clin Infect Dis. 2016 May 1;62(9):1178-1185. doi: 10.1093/cid/ciw065. Epub 2016 Feb 7.


Initiation of Antiretroviral Therapy Restores CD4+ T Memory Stem Cell Homeostasis in Simian Immunodeficiency Virus-Infected Macaques.

Cartwright EK, Palesch D, Mavigner M, Paiardini M, Chahroudi A, Silvestri G.

J Virol. 2016 Jul 11;90(15):6699-6708. doi: 10.1128/JVI.00492-16. Print 2016 Aug 1.


Interleukin-7 improves reconstitution of antiviral CD4 T cells.

Lu H, Zhao Z, Kalina T, Gillespy T 3rd, Liggitt D, Andrews RG, Maloney DG, Kiem HP, Storek J.

Clin Immunol. 2005 Jan;114(1):30-41.


Antibody-Mediated CD4 Depletion Induces Homeostatic CD4+ T Cell Proliferation without Detectable Virus Reactivation in Antiretroviral Therapy-Treated Simian Immunodeficiency Virus-Infected Macaques.

Kumar NA, McBrien JB, Carnathan DG, Mavigner M, Mattingly C, White ER, Viviano F, Bosinger SE, Chahroudi A, Silvestri G, Paiardini M, Vanderford TH.

J Virol. 2018 Oct 29;92(22). pii: e01235-18. doi: 10.1128/JVI.01235-18. Print 2018 Nov 15.


Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.


A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, Mugyenyi P, Boom WH, Mugerwa RD, Havlir DV, Whalen CC.

J Infect Dis. 2011 Sep 15;204(6):884-92. doi: 10.1093/infdis/jir503.


Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, Wilkinson RJ, McShane H; MVA85A 030 trial investigators.

Lancet Respir Med. 2015 Mar;3(3):190-200. doi: 10.1016/S2213-2600(15)00037-5. Epub 2015 Feb 26.


Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.

Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, Leroux-Roels G.

Vaccine. 2013 Aug 12;31(36):3739-46. doi: 10.1016/j.vaccine.2013.05.021. Epub 2013 May 21.


Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.

Soria A, Trabattoni D, Squillace N, Rainone V, Gnudi F, Clerici M, Gori A, Bandera A.

PLoS One. 2015 Feb 11;10(2):e0117118. doi: 10.1371/journal.pone.0117118. eCollection 2015.


Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection.

Thiébaut R, Drylewicz J, Prague M, Lacabaratz C, Beq S, Jarne A, Croughs T, Sekaly RP, Lederman MM, Sereti I, Commenges D, Lévy Y.

PLoS Comput Biol. 2014 May 22;10(5):e1003630. doi: 10.1371/journal.pcbi.1003630. eCollection 2014 May.


Short-term garlic supplementation and highly active antiretroviral treatment adherence, CD4+ cell counts, and human immunodeficiency virus viral load.

Liu C, Wang C, Robison E, Levine AM, Gandhi M, Schwartz R, Weber KM, Merenstein D.

Altern Ther Health Med. 2012 Jan-Feb;18(1):18-22.


Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.

Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, Dignat-George F, Poizot-Martin I.

AIDS. 2015 Jul 31;29(12):1505-10. doi: 10.1097/QAD.0000000000000650.


Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.

Choi YW, Kang MC, Seo YB, Namkoong H, Park Y, Choi DH, Suh YS, Lee SW, Sung YC, Jin HT.

Clin Cancer Res. 2016 Dec 1;22(23):5898-5908. Epub 2016 Jul 12.


Role of interleukin-2 in patients with HIV infection.

Pett SL, Kelleher AD, Emery S.

Drugs. 2010 Jun 18;70(9):1115-30. doi: 10.2165/10898620-000000000-00000. Review.


Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.


Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort.

Limou S, Melica G, Coulonges C, Lelièvre JD, Do H, McGinn S, Gut IG, Lévy Y, Zagury JF.

Curr HIV Res. 2012 Mar;10(2):143-50.


Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential.

Beq S, Delfraissy JF, Theze J.

Eur Cytokine Netw. 2004 Oct-Dec;15(4):279-89. Review.


Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.

Supplemental Content

Support Center